Anmeldung erfolgt in Kürze...
Details werden geladen...
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome | The Manila Times
NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designationsEcopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved. TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.
Ähnliche Seiten
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome | The Manila Times
https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/quoin-pharmaceuticals-submits-ind-application-for-qrx003-in-peeling-skin-syndrome/2356844Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1 | The Manila Times
https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/ambros-therapeutics-announces-first-patient-dosed-in-pivotal-crps-rise-phase-3-clinical-trial-of-neridronate-in-patients-with-complex-regional-pain-syndrome-type-1/2360811
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes | The Manila Times
https://www.manilatimes.net/2026/06/13/tmt-newswire/globenewswire/press-release-sanofis-tzield-approved-in-the-us-as-the-first-disease-modifying-therapy-for-patients-recently-diagnosed-with-stage-3-type-1-diabetes/2364747Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema | The Manila Times
https://www.manilatimes.net/2026/05/27/tmt-newswire/globenewswire/therini-bio-doses-first-patients-in-phase-1b-trial-of-novel-anti-inflammatory-therapy-thn391-for-diabetic-macular-edema/2352853Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia | The Manila Times
https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/cullinan-therapeutics-receives-fda-orphan-drug-designation-for-cln-049-a-novel-flt3xcd3-t-cell-engager-in-relapsedrefractory-acute-myeloid-leukemia/2347010